Table 3.
Observed (O) and expected (E) number of cancers in subjects with residence in the Schiphol area according to site, gender and period of diagnosis, 1988–2003
| cancer site (ICD-10 code) and gender | Total period (1988–2003) | 1988–1993 | 1994–1998 | 1999–2003 | ||||||||||||
| O | E | SIR | 95% CI | O | E | SIR | 95% CI | O | E | SIR | 95% CI | O | E | SIR | 95% CI | |
| All malignancies (C00–C96) | 13207 | 13007.9 | 1.02 | 1.00, 1.03 | 4624 | 4538.6 | 1.02 | 0.99, 1.05 | 4220 | 4125.1 | 1.02 | 0.99, 1.05 | 4363 | 4344.3 | 1.00 | 0.97, 1.03 |
| adult males | 6697 | 6713.7 | 1.00 | 0.97, 1.02 | 2402 | 2363.5 | 1.02 | 0.98, 1.06 | 2145 | 2150.3 | 1.00 | 0.96, 1.04 | 2150 | 2199.9 | 0.98 | 0.94, 1.02 |
| adult females | 6436 | 6235.3 | 1.03* | 1.01, 1.06 | 2190 | 2154.3 | 1.02 | 0.97, 1.06 | 2057 | 1956.5 | 1.05* | 1.01, 1.10 | 2189 | 2124.5 | 1.03 | 0.99, 1.07 |
| children <15 | 74 | 58.9 | 1.26 | 0.99, 1.58 | 32 | 20.7 | 1.54* | 1.06, 2.18 | 18 | 18.3 | 0.98 | 0.58, 1.55 | 24 | 19.9 | 1.21 | 0.77, 1.79 |
| Head & neck (C00–C14) | 282 | 272.9 | 1.03 | 0.92, 1.16 | 93 | 93.7 | 0.99 | 0.80, 1.22 | 91 | 85.9 | 1.06 | 0.85, 1.30 | 98 | 93.3 | 1.05 | 0.85, 1.28 |
| males | 162 | 176.9 | 0.92 | 0.78, 1.07 | 53 | 62.8 | 0.84 | 0.63, 1.10 | 56 | 55.6 | 1.01 | 0.76, 1.31 | 53 | 58.4 | 0.91 | 0.68, 1.19 |
| females | 120 | 96.0 | 1.25* | 1.04, 1.49 | 40 | 30.9 | 1.29 | 0.92, 1.76 | 35 | 30.3 | 1.16 | 0.80, 1.61 | 45 | 34.8 | 1.29 | 0.94, 1.73 |
| Gastrointestinal tract (C15–C26) | 2889 | 2936.0 | 0.98 | 0.95, 1.02 | 1034 | 1049.3 | 0.99 | 0.93, 1.05 | 899 | 920.4 | 0.98 | 0.91, 1.04 | 956 | 966.3 | 0.99 | 0.93, 1.05 |
| males | 1494 | 1538.0 | 0.97 | 0.92, 1.02 | 517 | 541.6 | 0.95 | 0.87, 1.04 | 470 | 482.3 | 0.97 | 0.89, 1.07 | 507 | 514.1 | 0.99 | 0.90, 1.08 |
| females | 1395 | 1398.1 | 1.00 | 0.95, 1.05 | 517 | 507.7 | 1.02 | 0.93, 1.11 | 429 | 438.1 | 0.98 | 0.89, 1.08 | 449 | 452.3 | 0.99 | 0.90, 1.09 |
| Respiratory system (C30–C34) | 1862 | 1975.1 | 0.94* | 0.90, 0.99 | 749 | 752.6 | 1.00 | 0.93, 1.07 | 542 | 627.1 | 0.86† | 0.79, 0.94 | 571 | 595.4 | 0.96 | 0.88, 1.04 |
| males | 1378 | 1548.0 | 0.89† | 0.84, 0.94 | 604 | 626.3 | 0.96 | 0.89, 1.01 | 386 | 492.7 | 0.78† | 0.71, 0.87 | 388 | 429.0 | 0.90 | 0.82, 1.00 |
| females | 484 | 427.1 | 1.13* | 1.03, 1.24 | 145 | 126.3 | 1.15 | 0.97, 1.35 | 156 | 134.5 | 1.16 | 0.98, 1.36 | 183 | 166.4 | 1.10 | 0.95, 1.27 |
| Breast (C50) | 2087 | 1983.6 | 1.05 | 0.99, 1.11 | 679 | 676.4 | 1.00 | 0.93, 1.08 | 678 | 620.3 | 1.09* | 1.01, 1.18 | 730 | 686.9 | 1.06 | 0.99, 1.14 |
| Female genital organs (C51–C58) | 710 | 730.7 | 0.97 | 0.90, 1.05 | 252 | 274.9 | 0.92 | 0.81, 1.04 | 237 | 232.9 | 1.02 | 0.89, 1.16 | 221 | 222.9 | 0.99 | 0.87, 1.13 |
| Prostate (C61) | 1291 | 1230.9 | 1.05 | 0.99, 1.11 | 382 | 364.6 | 1.05 | 0.95, 1.16 | 470 | 421.2 | 1.12* | 1.02, 1.22 | 439 | 445.2 | 0.99 | 0.90, 1.08 |
| Bladder & other urinary tract (C65–C68) | 543 | 517.2 | 1.05 | 0.96, 1.14 | 211 | 183.9 | 1.15 | 1.00, 1.31 | 172 | 163.7 | 1.05 | 0.90, 1.22 | 160 | 169.7 | 0.94 | 0.80, 1.10 |
| males | 425 | 390.0 | 1.09 | 0.99, 1.20 | 173 | 139.7 | 1.24† | 1.06, 1.44 | 129 | 123.6 | 1.04 | 0.87, 1.24 | 123 | 126.7 | 0.97 | 0.81, 1.16 |
| females | 118 | 127.3 | 0.93 | 0.77, 1.11 | 38 | 44.2 | 0.86 | 0.54, 1.29 | 43 | 40.1 | 1.07 | 0.78, 1.44 | 37 | 43.0 | 0.86 | 0.61, 1.19 |
| Hematological malignancies (C81–C96) | 1044 | 935.2 | 1.12† | 1.05, 1.19 | 367 | 328.3 | 1.12* | 1.01, 1.24 | 334 | 291.2 | 1.15* | 1.03, 1.28 | 343 | 315.8 | 1.09 | 0.97, 1.21 |
| males | 598 | 507.6 | 1.18† | 1.09, 1.28 | 210 | 177.3 | 1.18* | 1.03, 1.36 | 184 | 157.8 | 1.17 | 1.00, 1.35 | 204 | 172.6 | 1.18* | 1.03, 1.36 |
| females | 446 | 427.6 | 1.04 | 0.95, 1.14 | 157 | 151.0 | 1.04 | 0.88, 1.22 | 150 | 133.4 | 1.12 | 0.95, 1.32 | 139 | 143.2 | 0.97 | 0.82, 1.15 |
| Hodgkin lymphoma | 48 | 61.2 | 0.78 | 0.58, 1.04 | 19 | 23.6 | 0.81 | 0.48, 1.26 | 12 | 17.7 | 0.68 | 0.35, 1.18 | 17 | 19.9 | 0.85 | 0.50, 1.37 |
| non-Hodgkin lymphoma | 516 | 423.5 | 1.22† | 1.12, 1.33 | 176 | 150.0 | 1.17* | 1.01, 1.36 | 181 | 133.5 | 1.36† | 1.17, 1.57 | 159 | 140.0 | 1.14 | 0.97, 1.33 |
| plasma cell tumors | 169 | 156.1 | 1.08 | 0.93, 1.26 | 59 | 55.6 | 1.06 | 0.81, 1.37 | 56 | 51.3 | 1.09 | 0.82, 1.42 | 54 | 49.3 | 1.10 | 0.82, 1.43 |
| acute lymphoblastic leukemia | 39 | 29.1 | 1.34 | 0.95, 1.83 | 17 | 10.2 | 1.67 | 0.97, 2.67 | 8 | 8.8 | 0.91 | 0.39, 1.79 | 14 | 10.2 | 1.38 | 0.75, 2.30 |
| chronic lymphocytic leukemia | 92 | 101.2 | 0.91 | 0.73, 1.11 | 33 | 35.0 | 0.94 | 0.65, 1.32 | 29 | 35.2 | 0.82 | 0.55, 1.18 | 30 | 31.0 | 0.97 | 0.65, 1.38 |
| acute myeloid leukemia | 109 | 97.8 | 1.11 | 0.92, 1.34 | 40 | 33.9 | 1.18 | 0.84, 1.61 | 33 | 31.4 | 1.05 | 0.72, 1.48 | 36 | 32.4 | 1.11 | 0.78, 1.54 |
| other | 71 | 66.2 | 1.07 | 0.84, 1.35 | 23 | 20.1 | 1.15 | 0.73, 1.72 | 15 | 13.3 | 1.13 | 0.63, 1.86 | 33 | 32.8 | 1.00 | 0.69, 1.41 |
| Other sites | 2499 | 2426.3 | 1.03 | 0.99, 1.07 | 857 | 815.0 | 1.05 | 0.98, 1.12 | 797 | 762.4 | 1.05 | 0.97, 1.12 | 845 | 848.9 | 1.00 | 0.93, 1.06 |
| males | 1391 | 1355.5 | 1.03 | 0.97, 1.08 | 485 | 462.8 | 1.05 | 0.96, 1.15 | 462 | 427.2 | 1.08 | 0.99, 1.18 | 444 | 465.5 | 0.95 | 0.87, 1.05 |
| females | 1108 | 1070.8 | 1.03 | 0.97, 1.10 | 372 | 352.2 | 1.06 | 0.95, 1.17 | 335 | 335.2 | 1.00 | 0.90, 1.11 | 401 | 383.4 | 1.05 | 0.95, 1.15 |
* p < 0.05; † p < 0.01; CI = confidence interval; E = expected number; O = observed number; SIR = standardized incidence ratio